Anti-CCR5/ CC-CKR-5/ CCCKR5 monoclonal antibody
Anti-CCR5/ CC-CKR-5/ CCCKR5 antibody for FACS & in-vivo assay
Go to CCR5/CCR5 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T09960-Ab-1/ GM-Tg-hg-T09960-Ab-2 | Anti-Human CCR5 monoclonal antibody | Human |
GM-Tg-rg-T09960-Ab-1/ GM-Tg-rg-T09960-Ab-2 | Anti-Rat CCR5 monoclonal antibody | Rat |
GM-Tg-mg-T09960-Ab-1/ GM-Tg-mg-T09960-Ab-2 | Anti-Mouse CCR5 monoclonal antibody | Mouse |
GM-Tg-cynog-T09960-Ab-1/ GM-Tg-cynog-T09960-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CCR5 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T09960-Ab-1/ GM-Tg-felg-T09960-Ab-2 | Anti-Feline CCR5 monoclonal antibody | Feline |
GM-Tg-cang-T09960-Ab-1/ GM-Tg-cang-T09960-Ab-2 | Anti-Canine CCR5 monoclonal antibody | Canine |
GM-Tg-bovg-T09960-Ab-1/ GM-Tg-bovg-T09960-Ab-2 | Anti-Bovine CCR5 monoclonal antibody | Bovine |
GM-Tg-equg-T09960-Ab-1/ GM-Tg-equg-T09960-Ab-2 | Anti-Equine CCR5 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T09960-Ab-1/ GM-Tg-hg-T09960-Ab-2; GM-Tg-rg-T09960-Ab-1/ GM-Tg-rg-T09960-Ab-2; GM-Tg-mg-T09960-Ab-1/ GM-Tg-mg-T09960-Ab-2; GM-Tg-cynog-T09960-Ab-1/ GM-Tg-cynog-T09960-Ab-2; GM-Tg-felg-T09960-Ab-1/ GM-Tg-felg-T09960-Ab-2; GM-Tg-cang-T09960-Ab-1/ GM-Tg-cang-T09960-Ab-2; GM-Tg-bovg-T09960-Ab-1/ GM-Tg-bovg-T09960-Ab-2; GM-Tg-equg-T09960-Ab-1/ GM-Tg-equg-T09960-Ab-2 |
Products Name | Anti-CCR5 monoclonal antibody |
Format | mab |
Target Name | CCR5 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CCR5 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Biosimilar | GMP-Bios-ab-304 | Pre-Made Leronlimab biosimilar, Whole mAb, Anti-CCR5 Antibody: Anti-CKR5/CCR-5/CD195/CKR-5/CCCKR5/CMKBR5/IDDM22/CC-CKR-5 therapeutic antibody |
Target Antigen | Products Developing | Multi-species CCR5/ CC-CKR-5/ CCCKR5 VLP (virus-like particle) (Products Developing) |
Cytokine | GM-Tg-g-T09960-Ag-1 | chemokine (C-C motif) receptor 5 (CCR5) protein |
ORF Viral Vector | pGMLP003863 | human CCR5 Lentivirus plasmid |
ORF Viral Vector | vGMLP003863 | human CCR5 Lentivirus particle |
Target information
Target ID | GM-T09960 |
Target Name | CCR5 |
Gene ID | 1234,735311,100048935 |
Gene Symbol and Synonyms | CC-CKR-5,CCCKR5,CCR-5,CCR5,CD195,CKR-5,CKR5,CMKBR5,IDDM22 |
Uniprot Accession | P51681,P61813 |
Uniprot Entry Name | CCR5_HUMAN,CCR5_MACMU |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target |
Disease | HIV infection |
Gene Ensembl | ENSG00000160791 |
Target Classification | Checkpoint-Immuno Oncology, GPCR |
The target: CCR5, gene name: CCR5, also named as CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22. This gene encodes a member of the beta chemokine receptor family, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. Defective alleles of this gene have been associated with the HIV infection resistance. The ligands of this receptor include monocyte chemoattractant protein 2 (MCP-2), macrophage inflammatory protein 1 alpha (MIP-1 alpha), macrophage inflammatory protein 1 beta (MIP-1 beta) and regulated on activation normal T expressed and secreted protein (RANTES). Expression of this gene was also detected in a promyeloblastic cell line, suggesting that this protein may play a role in granulocyte lineage proliferation and differentiation. This gene is located at the chemokine receptor gene cluster region. An allelic polymorphism in this gene results in both functional and non-functional alleles; the reference genome represents the functional allele. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.